Natera
Genetic testing for cancer, transplant, pregnancy
Clinical Oncology Specialist - Breast
+ Uncapped quarterly commissions + Car allowance + Restricted Stock Units (RSUs)
More locations: Portland, OR, USA
The territory covers Oregon, Washington, Idaho, Montana, Utah and Wyoming. Travel is approximately 75%, including road and air travel and overnight trips as needed.
About the job
- A bachelor's degree is required.
- Five or more years of successful experience in breast oncology, surgical sales, or molecular diagnostics is preferred.
- Deep knowledge of academic and community oncology markets, precision medicine, and the reimbursement landscape is required.
- Ability to travel frequently, including overnight travel as needed, is required.
- A valid driver's license and safe driving record are required.
- Proven leadership, business acumen, and strong communication skills are required.
- Excellent verbal, written, and presentation skills are required.
- A strong clinical understanding of oncology and molecular diagnostics is required.
- Ability to navigate complex healthcare systems and engage senior stakeholders is required.
- Ability to work independently and collaboratively in team environments is required.
- Develop and execute a strategic territory plan focused on growth and account penetration.
- Identify and engage key opinion leaders and key accounts to integrate Signatera into clinical decision-making.
- Drive new business development while expanding and deepening existing relationships.
- Maximize return on investment through consistent sales activity and cross-functional collaboration.
- Deliver clinical education to physicians and care teams.
- Build an understanding of Natera's oncology solutions, internal processes, and competitor landscape.
- Call on targeted physicians and practices to promote Natera's oncology products and services.
- Drive product adoption by influencing clinical decision-making at the provider and system level.
- Monitor account performance and market trends, escalate issues, and identify new opportunities.
- Conduct business in an ethical, transparent, and professional manner.
- Five or more years of successful experience in breast oncology, surgical sales, or molecular diagnostics.
About the company
Natera provides genetic testing and diagnostics using cell-free DNA (cfDNA) from a patient’s blood to guide medical decisions. Its tests include MRD and ctDNA profiling for cancer, the personalized Signatera test, organ transplant health assessment, and Panorama NIPT for prenatal screening. The company combines cfDNA-based results with remote access and genetic counseling to support clinicians and patients. Its goal is to deliver accurate, noninvasive tests that improve treatment decisions and patient outcomes at scale.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Austin, Texas
Founded
2004
Get referred to Natera
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $752.8 million, up 37.7%, and guidance rose to $2.85-2.91 billion.
- Signatera volumes reached 283,000 units in Q2 2026, proving commercial pull across tumor types.
- Japan bladder-cancer launch in 2027 plus EU IVDR access extends Signatera’s addressable market sharply.
What critics are saying
- August 2026 class-action settlement over Panorama closes one reputation wound, not the litigation burden.
- Schneider securities suit, Copley billing claims, and Klein PGT-A litigation keep legal overhang alive.
- ArcherDX’s September 2026 Federal Circuit appeal threatens Natera’s patent moat and future MRD pricing.
What makes Natera unique
- Natera’s Signatera owns tumor-informed MRD with PMDA and FDA bladder-cancer approvals, August 2026.
- June 2026 PMDA approval made Signatera Japan’s first approved MRD test in colorectal cancer.
- Natera combines oncology, prenatal, and transplant testing on one cfDNA platform, widening physician penetration.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible medical plans
Investment options
Time off
Workplace perks
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 1%Natera's Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency as a companion diagnostic for muscle-invasive bladder cancer. The approval supports Signatera-guided decisions for adjuvant atezolizumab treatment and marks the company's second PMDA authorisation for Signatera in three months. Natera plans to commercially launch Signatera for MIBC in Japan in the first half of 2027. The regulatory approval was supported by data from the IMvigor011 Phase III clinical trial, which included more than 20 participating sites in Japan. Bladder cancer affects more than 34,000 people annually in Japan, with approximately 20-25% of newly diagnosed cases classified as MIBC. Following the announcement, Natera stock gained 5.5%.
Natera presents largest MRD dataset in lung cancer at IASLC 2026 world conference. Published on 09/18/2026 at 07:05 am EDT S&P Capital IQ Natera and its collaborators presented four abstracts, including two oral presentations. A mini-oral presentation featured the largest molecular residual disease (MRD) dataset ever presented in lung cancer. This analysis of 1,129 patients with resected stage 1-3 non-small cell lung cancer (NSCLC) spanned an observation period from 2016 to 2025. Signatera MRD detection was evaluated in the early post-surgical window and throughout surveillance, with the following key findings: Early post-surgical Signatera-status was strongly prognostic of recurrence-free survival. Signatera-positivity in the early post-surgical window (7?90 days after surgery) was associated with significantly worse recurrence-free survival (RFS), with a 25% higher absolute 3-year RFS for Signatera-negative patients. Signatera-positive patients had approximately 5X the risk of recurrence or death during surveillance. Findings were consistent across both the primary surgical and perioperative cohorts, supporting broad applicability of Signatera monitoring across resected stage 1-3 NSCLC. Full list of presentations at WCLC 2026 included: Abstract P2.192 Poster: ctDNA After Definitive Therapy +/- Immunotherapy and Association with Survival Outcomes in Locally Advanced Unresectable NSCLC. Abstract P2.200 Poster: ctDNA-based Molecular Residual Disease as a Predictive Biomarker for Treatment Stratification in Unresectable Stage 3 NSCLC. Abstract MO05.07 Mini Oral: KRAS G12C Predicts Superior Outcomes with 1L Cemiplimab for Non-Squamous aNSCLC With PD-L1 = 50%: Data From EMPOWER-Lung 1. Abstract MO11.09 Mini Oral: Post-Surgical Molecular Residual Disease Detection, Adjuvant Treatment Patterns, and Overall Survival in Resected Stage 1-3 NSCLC. (C) S&P Capital IQ - 2026
Natera teams with Angiex on cancer drug trial monitoring. * August 31, 2026 Natera inked a collaboration deal with biotech Angiex to assess the use of its Signatera blood test, which looks for small traces of cancer DNA in patients who have been diagnosed and treated for the disease.
Natera has partnered with Kupando Therapeutics to supply its Latitude tissue-free minimal residual disease (MRD) assay for a Phase 1 immunotherapy trial in multiple skin cancers. The assay will monitor disease and treatment response in patients receiving Kupando's investigational therapy. The collaboration extends Natera's MRD technology into early-stage drug development settings. Natera is a US-based molecular diagnostics company that develops and commercialises testing services. The partnership expands Natera's presence in oncology clinical trials and supports use of its MRD technology across different tumour types. However, the revenue impact from these early-stage trial deployments is likely modest at this stage. Investors will watch whether additional oncology trials adopt Natera's platforms and if the company begins disclosing trial counts or patient volumes linked to MRD collaborations.
Natera reported second-quarter results that beat analyst expectations, driven by strong test volume growth and momentum across its product portfolio. Revenue reached $752.8 million, exceeding estimates by 13.6%, whilst adjusted EPS of -$0.47 beat forecasts. CEO Steven Chapman attributed the performance to record test volumes, particularly for Signatera in oncology, and the launch of an enhanced Panorama prenatal test. The company secured FDA and Japanese regulatory approvals for Signatera during the quarter. Operating margin improved to -10.1% from -20.2% year on year. Sales volumes rose 22.4% compared to the prior year. During the earnings call, analysts questioned the sustainability of Signatera's growth trajectory and future pricing potential. Chapman acknowledged emerging competition in MRD testing but noted that low market penetration leaves substantial room for expansion.